Literature DB >> 24440181

The relative frequency of CFTR mutation classes in European patients with cystic fibrosis.

K De Boeck1, A Zolin2, H Cuppens3, H V Olesen4, L Viviani2.   

Abstract

More than 1900 different mutations in the CFTR gene have been reported. These are grouped into classes according to their effect on the synthesis and/or function of the CFTR protein. CFTR repair therapies that are mutation or mutation class specific are under development. To progress efficiently in the clinical phase of drug development, knowledge of the relative frequency of CFTR mutation classes in different populations is useful. Therefore, we describe the mutation class spectrum in 25,394 subjects with CF from 23 European countries. In 18/23 countries, 80% or more of the patients had at least one class II mutation, explained by F508del being by far the most frequent mutation. Overall 16.4% of European patients had at least one class I mutation but this varied from 3 countries with more than 30% to 4 countries with less than 10% of subjects. Overall only respectively 3.9, 3.3 and 3.0% of European subjects had at least one mutation of classes III, IV and V with again great variability: 14% of Irish patients had at least one class III mutation, 7% of Portuguese patients had at least one class IV mutation, and in 6 countries more than 5% of patients had at least one class V mutation.
Copyright © 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Allele frequency; CFTR mutation classes; CFTR mutations; Cystic fibrosis; Genotype; Prevalence

Mesh:

Substances:

Year:  2014        PMID: 24440181     DOI: 10.1016/j.jcf.2013.12.003

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  52 in total

Review 1.  Ionotropic GABA and Glutamate Receptor Mutations and Human Neurologic Diseases.

Authors:  Hongjie Yuan; Chian-Ming Low; Olivia A Moody; Andrew Jenkins; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2015-04-22       Impact factor: 4.436

2.  Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012.

Authors:  Abaigeal D Jackson; Andrew L Jackson; Godfrey Fletcher; Gerardine Doyle; Mary Harrington; Shijun Zhou; Fiona Cullinane; Charles Gallagher; Edward McKone
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981

Review 3.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

4.  Inhibition of calpain 1 restores plasma membrane stability to pharmacologically rescued Phe508del-CFTR variant.

Authors:  Ana M Matos; Francisco R Pinto; Patrícia Barros; Margarida D Amaral; Rainer Pepperkok; Paulo Matos
Journal:  J Biol Chem       Date:  2019-07-19       Impact factor: 5.157

5.  Distinctive metabolic profiles between Cystic Fibrosis mutational subclasses and lung function.

Authors:  Afshan Masood; Minnie Jacob; Xinyun Gu; Mai Abdel Jabar; Hicham Benabdelkamel; Imran Nizami; Liang Li; Majed Dasouki; Anas M Abdel Rahman
Journal:  Metabolomics       Date:  2021-01-04       Impact factor: 4.290

6.  Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study.

Authors:  Tomáš Mlčoch; Jiří Klimeš; Libor Fila; Věra Vávrová; Veronika Skalická; Marek Turnovec; Veronika Krulišová; Jitka Jirčíková; Dana Zemková; Klára Vilimovská Dědečková; Alena Bílková; Vladimíra Frühaufová; Lukáš Homola; Zuzana Friedmannová; Radovan Drnek; Pavel Dřevínek; Tomáš Doležal; Milan Macek
Journal:  Eur J Health Econ       Date:  2016-01-07

Review 7.  CFTR potentiators: from bench to bedside.

Authors:  Kang-Yang Jih; Wen-Ying Lin; Yoshiro Sohma; Tzyh-Chang Hwang
Journal:  Curr Opin Pharmacol       Date:  2017-11-05       Impact factor: 5.547

Review 8.  Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function.

Authors:  Emer P Reeves; Cormac McCarthy; Oliver J McElvaney; Maya Sakthi N Vijayan; Michelle M White; Danielle M Dunlea; Kerstin Pohl; Noreen Lacey; Noel G McElvaney
Journal:  World J Crit Care Med       Date:  2015-08-04

Review 9.  Molecular basis of cystic fibrosis: from bench to bedside.

Authors:  Maria Cristina Dechecchi; Anna Tamanini; Giulio Cabrini
Journal:  Ann Transl Med       Date:  2018-09

Review 10.  Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis.

Authors:  Elena K Schneider-Futschik
Journal:  Gene Ther       Date:  2019-07-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.